Jan Meiners, Kristina Jansen, Natalia Gorbokon, Franziska Büscheck, Andreas M Luebke, Martina Kluth, Claudia Hube-Magg, Doris Höflmayer, Sören Weidemann, Christoph Fraune, Katharina Möller, Christian Bernreuther, Patrick Lebok, Anne Menz, Frank Jacobsen, Till Clauditz, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Jakob Izbicki, Daniel Perez, Sarah Minner, Eike Burandt, Till Krech, Andreas Marx, Ronald Simon, Stefan Steurer
Angiotensin-converting enzyme 2 (ACE2) is a regulator in the renin-angiotensin system. ACE2 expression was analysed immunohistochemically in 15,306 samples from 119 tumour types and in 608 samples of 76 normal tissue types. In normal tissue, ACE2 was most abundant in testis and corpus luteum, kidney, small intestine and capillaries of selected organs. At least an occasional weak ACE2 positivity of tumour cells was seen in 83 of 119 (70%) tumour types. ACE2 tumour cell positivity was particularly frequent in papillary (94%) and clear cell (86%) renal cell carcinoma, colorectal adenocarcinoma (81%), mucinous ovarian cancer (61%), cholangiocarcinoma (58%), hepatocellular carcinoma (56%), and in adenocarcinomas of the stomach (47%), pancreas (42%), and the lung (35%)...
December 3, 2021: Biomedicines